Study of MVI-118 Prostate Cancer Vaccine Expands, Adding Site in Seattle

Study of MVI-118 Prostate Cancer Vaccine Expands, Adding Site in Seattle
A Phase 1 study evaluating the MVI-118 cancer vaccine in patients with metastatic prostate cancer is expanding to a third clinical site, the University of Washington in Seattle. The trial is studying whether MVI-118 can be used in combination with androgen deprivation therapy (ADT) to delay treatment resistance and prolong disease control in patients whose

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *